CRMD
CorMedixANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The Q1 print was a clear operating beat, management raised 2026 guidance, and the company still has multiple longer-dated upside levers in REZZAYO and DefenCath expansion [#8-K-2026-05-14] [#10-Q-2026-05-14].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Analyst revision coverage is unavailable here, so post-print expectations may be less validated than the headline price move implies.
Momentum
65
Value
68
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.50 · Bull $17.00 · Bear $6.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $14.86
Why
Momentum65 · Δ7d +3.9
Value68 · Δ7d -0.3
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
65
34% active weight
Current posture
7d trendImproving
Δ7d
+3.9
Δ21d
+21.0
Value
68
32% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.3
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+24.6
Why this grade
Composite grade A. Momentum 64.7 / Value 68.2 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$662.92M
Beta
1.40
Shares Out
78.79M
P/E (TTM)
5.9
P/S (TTM)
4.48
P/FCF (TTM)
12.91
Rev YoY
+810.2%
EPS YoY
+2767.8%
Gross Margin
+92.6%
Op Margin
+48.5%
Net Debt
-$51.69M
Current Ratio
1.94
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology